Extended PBS Access to Zoladex

AstraZeneca has announced that Zoladex (goserelin 3.6 mg implant) will remain on the Pharmaceutical Benefits Scheme (PBS) until 1 May 2027, after which it will move to a “supply only” arrangement. Prescriptions written before that date may continue to be dispensed for up to 12 months, enabling eligible patients to access PBS-subsidised treatment through to 1 May 2028.

AstraZeneca understands the importance of maintaining PBS access to this therapy and applied for a price increase for the Zoladex monthly (3.6mg) implant to remain on the PBS. The Pharmaceutical Benefits Advisory Committee (PBAC) was unable to grant a price adjustment that would have allowed the continued PBS reimbursement of this medicine.

AstraZeneca will consider making a further application to the PBAC to secure long-term reimbursed access for the Zoladex monthly (3.6mg) implant.

With alternatives now available to Australian patients through the PBS, the previously announced Zoladex continuity program will not proceed.

The separate Zoladex three-monthly (10.8mg) implant is now registered with the Therapeutic Goods Administration for the management of oestrogen-receptor (ER) positive early and advanced breast cancer in pre and peri menopausal women. AstraZeneca awaits the outcome of the PBAC’s evaluation of our submission for a PBS listing of this indication.

Questions can be referred to AstraZeneca’s Medical Information team or over the phone on 1800 805 342.